Should You Buy aTyr Pharma, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, aTyr Pharma, Inc. (ATYR) scores 5.0/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.39, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 2 of 2 CirclFi valuation models project upside for aTyr Pharma, Inc. (ATYR) at $0.39 — the model consensus leans bullish, with a Quality Score of 5.0/10 and Value-Trap risk of 63/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for aTyr Pharma, Inc. (ATYR) in 2026?
What Is the Bull Case vs the Bear Case for aTyr Pharma, Inc. (ATYR)?
| Bull case — $0.73 target (+87.6%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $0.39 and the median fair value of $0.68 implies +75.1% upside potential. | No active model flags significant downside for ATYR. The Value Trap score of 63/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $0.73 (+87.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: first-mover advantage in novel targets could provide meaningful support for aTyr Pharma, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does ATYR Compare to Its Biotechnology Peers?
Valuation data pages: ZBIO · CADL · CVKD · BLTE · LIPO · IMMX · AZTR · EVAX · LPCN · EXEL · INCY
Which Other Stocks Score Like ATYR on Quality?
Closest companies to ATYR’s Quality of Company score of 5.0/10, across all industries.
Which Biotechnology Screens Does ATYR Appear In?
So Is aTyr Pharma, Inc. (ATYR) Worth Buying in 2026?
The convergence of 5.0/10 quality, multi-model undervaluation (2/2 bullish, +75.1% median upside), and a median fair value of $0.68 vs. $0.39 current price makes aTyr Pharma, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. aTyr Pharma, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ATYR Stock?
Should I buy ATYR stock right now?
Based on CirclFi's multi-model analysis, 2 of 2 models see upside for ATYR at $0.39. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in aTyr Pharma, Inc.?
Key risks include: an elevated Value Trap score of 63/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ATYR compare to its competitors?
Among Biotechnology peers, ATYR holds a Quality Score of 5.0/10. Comparable companies include ZBIO (QOC 5.0), CADL (QOC 5.0), CVKD (QOC 5.1). The relative ranking helps investors identify whether ATYR offers better fundamental quality than alternatives in the same sector.
Is ATYR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATYR's Quality Score of 5.0/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ATYR at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.63 to $0.73. At $0.39, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ATYR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad